Highest-materiality recent filing
Aptar Q1 adjusted EPS $1.19 (-8% YoY); names Gael Touya CEO effective Sept 1
Reported sales up 11% to $982.9M; core sales flat; net income down 8% to $73M.
AptarGroup CEO Stephan Tanda to retire Sept 1, 2026; Gael Touya appointed successor
CEO Tanda to retire effective Sep 1, 2026; will serve as strategic advisor through Dec 31, 2026 and remain on Board until year-end.
Aptar Q4 net income down 26%, adjusted EPS $1.25 vs $1.62; new $600M buyback
Reported sales +14% to $963M (core +5%); net income -26% to $74M ($1.13 EPS).
AptarGroup closes $600M offering of 4.750% Senior Notes due 2031
$600M principal; 4.750% coupon, semi-annual; matures March 30, 2031.
Reported sales $961M (+6% YoY); core sales +1%. Reported EPS $1.92 (+30%); adjusted EPS $1.62 (+4%).
AptarGroup Q2 2025: adj. EPS $1.66 (+18% YoY), sales $966M (+6%), adj. EBITDA margin 22.6%
Reported sales $966M (+6% YoY); core sales +3%; net income $112M (+24%); adj. EPS $1.66 vs $1.41.
AptarGroup Q1 2025: sales down 3% to $887M, adjusted EPS $1.20, guides Q2 EPS $1.56-$1.64
Reported sales down 3% to $887M; net income down 5% to $79M; adjusted EPS $1.20 vs $1.22 prior year.
AptarGroup Q4 net income +62% to $101M; adj. EPS $1.52; pharma sales +8% FY
Q4 reported EPS $1.49 (+60% YoY); adjusted EPS $1.52 (+27% YoY).
Aptar reports Q3 net income $100M (+19%), adjusted EPS $1.49 (+6%)
Revenue $909M (+2% core sales); Pharma segment core sales +7%, Beauty -6%, Closures +4%.
Aptar reports Q2 EPS $1.34 (+8% YoY); raises dividend 10% to $0.45
Revenue $910M (+2% reported, +3% core); net income $90M (+9%).
Aptar CFO Bob Kuhn to retire Dec 31; Vanessa Kanu named successor effective Jan 1, 2025
Kuhn, CFO since 2008 and 37-year Aptar veteran, steps down Dec 31, 2024; also resigns as principal accounting officer July 31.
AptarGroup enters new credit agreement with $600M revolver and $330M term loan
New $330M unsecured term loan facility maturing July 2, 2027; revolving credit facility extended to July 2, 2029.
Aptar Q1 EPS $1.23 ($1.26 adj) up 50% (31% adj); revenue $915M +6%
Reported net income $83M (+52%); adjusted EBITDA $179M (+16%).
Aptar Q4 adjusted EPS $1.21 (up 27%), FY 2023 revenue $3.49B, guides Q1 2024 EPS $1.10-$1.18
Q4 reported sales $838M (+5%), net income $62M (+6%), adjusted EPS $1.21 vs $0.95 (up 27%).
Aptar Q3 adjusted EPS $1.39 (+39%), net income $84M (+55%), sales $893M (+7%)
Net income $84M (+55% YoY), reported EPS $1.26, adjusted EPS $1.39 (+39% YoY).
AptarGroup Q2 net income +31% to $83M; raises dividend 8% to $0.41/share
Reported EPS $1.24, adjusted EPS $1.23 (+26% YoY); revenue $896M (+6% reported, +4% core).
AptarGroup Q1 core sales +4% to $860M; adj. EPS $0.95; guides Q2 adj. EPS $1.11-$1.19
Reported sales $860M (+2% YoY); core sales +4% driven by Pharma (+7%) and Beauty (+9%); Closures -8%.
AptarGroup realigns segments into Pharma, Beauty, Closures; recasts 2022 & 2021 data
Effective Jan 1, 2023: combined all closures into Aptar Closures; renamed Beauty+Home to Aptar Beauty.
AptarGroup Q4 core sales up 4%, adjusted EPS $0.92; guides Q1 $0.85-$0.93
Q4 net income $59M (+2%), reported sales $796M (-2%), core sales +4%; adj EPS $0.92 (+5%).
AptarGroup Q3 net income +15% to $54M; core sales +9%; adj EPS $0.95
Reported net income $54M (+15%), EPS $0.81 (+16%) vs $0.70.
AptarGroup Q2 net income up 15% to $64M; core sales +10%; adjusted EPS $0.96
Reported sales $845M (+4% YoY); core sales +10%; net income $64M (+15%).
AptarGroup Q1 revenue up 9% to $845M; adjusted EPS down to $0.96 from $1.05
Reported sales $845M (+9% YoY); core sales +13% with double-digit growth in all segments.
AptarGroup issues $400M 3.600% senior notes due 2032, assumes €300M in subsidiary notes
Issued $400M aggregate principal of 3.600% Senior Notes due March 15, 2032, with semi-annual interest.
AptarGroup Q4 sales up 9% to $814M; adjusted EPS $0.93 (+3%); guides Q1 adj. EPS $0.92-$1.00
Q4 reported EPS $0.85 (+8% YoY); adjusted EPS $0.93 (+3% YoY). Net income $58M.
AptarGroup Q3 revenue $825M (+9% YoY); adjusted EPS $0.94 vs $1.01; guides Q4 $0.88-$0.96
Reported sales $825M, +9% YoY; core sales +8%; Pharma core -2%, Beauty+Home +10%, Food+Beverage +28%.
Aptar Q2 sales up 16% to $811M, adj EPS $0.91 (+7%), core sales +10%; Q3 guidance $0.90-$0.98
Reported sales $811M (+16% YoY); core sales +10% aided by double-digit growth in Beauty+Home and Food+Beverage.
Vanessa Kanu will succeed Mr. Kuhn as Executive Vice President, Chief Financial Officer of the Company, effective January 1, 2025.
Daniel Ackerman, age 51, Vice President, Corporate Controller of the Company since 2015, will become the Company’s Chief Accounting Officer, effective August 1, 2024.
and will retire as the Company’s principal accounting officer on July 31, 2024.
appointed Sarah Glickman as a director effective as of such date.
On July 9, 2023, after many years of service, Maritza Gomez Montiel notified AptarGroup, Inc. (the “Company”) of her decision to resign from the Board of Directors of the Company, effective immediately.
On May 6, 2023, after many years of service, Andreas Kramvis resigned from the Board of Directors of AptarGroup, Inc., effective immediately.
On March 1, 2023, the Board of Directors (the “Board”) of AptarGroup, Inc. (the “Company”) appointed Julie Xing as a director effective as of such date.
On September 11, 2022, the Board of Directors (the “Board”) of AptarGroup, Inc. (the “Company”) appointed Matthew L. Trerotola as a director effective as of such date.
Max materiality 0.80 · Median 0.65 · Most common event earnings